ACET Historical PE Ratio Notes

— Adicet Bio (NASDAQ: ACET) is a biotechnology company focused on the discovery & development of allogeneic gamma delta T cell therapies for cancer and other indications. Unlike traditional therapies, Adicet is pursuing innovative off-the-shelf cell therapies that are engineered from healthy donor cells rather than the patient’s own, aiming to deliver potent immunotherapy in a scalable, cost-effective way. Because Adicet is in the clinical-stage biotech sector, its revenues are minimal & largely driven by research milestones, grants, or limited collaborations; operating losses are typical as the company invests heavily in R&D without a marketed product. This means historical earnings are generally negative or highly volatile, often resulting in a negative or non-meaningful PE ratio. When you look at ACET’s historical PE ratios, you may notice many periods where PE is not calculated, as the “E” (earnings) is negative. For years when the company has occasional income (from licensing, for example), the PE might show a temporary figure, but is not typically useful for evaluating a company at this stage. In biotech, investors frequently value companies on potential future earnings rather than historical PE ratios.

On this page we presented the ACET Historical PE Ratio information for Adicet Bio' stock. The average ACET historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 79.9. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ACET historical PE based on this TTM earnings result method is 92.3. Note: any PE calculations resulting in a value exceeding 500 were discarded as not meaningful. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ACET historical PE result, against the recent PE: when this page was posted on 6/1/2026, the most recent closing price for ACET had been 8.78, and the most recent quarterly earnings result, annualized, was 6.4. Meanwhile, the most recent TTM earnings summed to 0.8. From these numbers, we calculate the recent ACET PE on 6/1/2026 based on annualized quarterly EPS was 1.4. Based on ACET's history, that recent PE is low relative to the historical average, with the recent PE 98.2% lower than the historical average PE across our data set for Adicet Bio. Looking at the recent ACET PE on 6/1/2026 based on TTM EPS, we calculate the ratio at 11.0. Based on ACET's history, that recent PE is low relative to the historical average, with the recent PE 88.1% lower than the average PE across our Adicet Bio data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ACET or any other given stock, valuation analysis for ACET can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Adicet Bio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ACET. Thanks for visiting, and the next time you need to research ACET Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.